This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer.
Beta Drugs offers a broad product portfolio across major oncology segments, including chemotherapy, targeted, hormonal and supportive therapy. The company was also honoured with the Forbes “Best Under a Billion” award in 2024.
At ASCO, one of the most talked-about studies was a late-stage trial in which the treatment outperformed chemotherapy as a first-line drug. As we move earlier, almost all of our trials will be in combination with different [immuno-oncology] drugs and … even chemotherapy drugs,” Keller said. “As
14,15 Lung Cancer Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post Progression Tarlatamab has shown promising efficacy in relapsed SCLC based on the initial single-arm trial findings, leading to an FDA approval in 2024, but challenges with administration have limited its widespread adoption.
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. 5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. June 21, 2024. Hemasphere.
2024 Global Strategy for Asthma Mnagement and Prevention Guidelines. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Charlotte, NC; June 9, 2025. Accessed June 9, 2025.
Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
The standard of care for RM-NPC in India before Toripalimab was chemotherapy (gemcitabine and cisplatin). Additionally, Toripalimab has also been approved as monotherapy for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. billion in July 2024. Within a week, he developed severe neutropenia, gastrointestinal shutdown, and septic complications requiring admission to the intensive care unit.
Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.
Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. This study explored the understudied area of health-related social needs (HRSNs) in the context of patients receiving chemotherapy.
The field is expanding into autoimmune diseases, with nononcology trials representing 51% of the pipeline by late 2024. Development Trends: Oncology at the Forefront Gene therapy currently ranks third among therapeutic focus areas, with 2151 compounds in development in 2024 ( Figure ).
August 8, 2024. Updated January 19, 2024. LinkedIn Workplace Learning Report 2024. American Oncology Network. Accessed May 15, 2025. How your oncology peers manage the complexities of care. Oncology Live ®. December 13, 2018. Accessed May 15, 2025. Desimone R. Improve work performance with a focus on employee development.
Conclusions We demonstrated the feasibility of leveraging a complex EHR data source from an integrated health system to study the impact of dose modifications on clinical outcomes for self-administered chemotherapy. Nearly half of the patients with CML on imatinib experienced dosage modifications in this study. HOPA has selected 4.0
After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects. January 17, 2024. 2024;25(1):336. doi:10.1186/s13063-024-08174-x 7. Pharmacy Times.
Additionally, patients may have received prior chemotherapy for advanced disease. In TRUST-II, treatment with taletrectinib achieved a cORR of 62%, and as of October 2024 (the time of data cut-off), the median DOR was 19.4 Updated November 21, 2024. months with a median follow-up of 19 months. Updated October 30, 2023.
Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. By GlobalData Learn more about Strategic Intelligence These concerns were made clear on 14 April 2024, when the European Parliament assigned its position of a baseline RDP at 7.5 Don’t let policy changes catch you off guard.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
Only 4% of global drugs sales will have patent protection, compared to 12% and 6% in 2022 and 2024. Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. A recent report by GlobalData projects that the share of global drug sales under patent protection will decline by 2030.
doi:10.1136/heartjnl-2024-325429. Storck W, Elbaz M, Vindis C, Déguilhem A, Lapeyre-Mestre M, Jouanjus E. Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis. 2025;0:1–10. Marijuana use dramatically increases risk of dying from heart attacks and stroke, large study finds. CNN Health.
In June 2025, the European Commission authorised Takeda’s Adcetris (brentuximab vedotin), an antibody-drug conjugate, combined with chemotherapy for treating adults who are newly diagnosed with Stage IIb Hodgkin’s lymphoma with risk factors or at Stage III/IV. Sign up for our daily news round-up!
In a press release, Theramex estimated that more than 1000 postmenopausal women in Scotland would be eligible for treatment, with SMC’s recommendation following a previous one made in August 2024 by the National Institute for Health and Care Excellence (NICE) governing abaloparatide’s status in England, Wales, and Northern Ireland (1).
1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.
Go deeper with GlobalData Reports LOA and PTSR Model - Denosumab Biosimilar in Bone Metastasis Reports LOA and PTSR Model - Denosumab Biosimilar in Chemotherapy Effects Data Insights The gold standard of business intelligence. By inhibiting RANKL, denosumab hampers the bone degradation process, bolstering bone density and strength.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
Find out more J&J’s drug is an option for patients where medical or surgical treatment to lower testosterone levels has not worked, and in those who have BRCA 1/2 mutations – a subset of homologous recombination repair (HRR) mutations – in whom chemotherapy is not indicated.
Imfinzi is now approved to treat adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with chemotherapy drugs gemcitabine and cisplatin as neoadjuvant treatment, and as a monotherapy after bladder removal surgery. Imfinzi is a major revenue driver for AstraZeneca, generating around $4.7bn in sales in 2024.
Dizal has received US Food and Drug Administration (FDA) approval for Zegfrovy (sunvozertinib) to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), following progression on or after receiving platinum-based chemotherapy.
Granted accelerated approval by the FDA in 2024, tarlatamab continues to demonstrate efficacy and safety in patients with small cell lung cancer, with results showing improved overall survival and progression-free survival in patients who had progressed or previously received chemotherapy.
Datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc) received FDA approval for treatment of adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. December 9, 2024. AstraZeneca.
Find out more about the event here: [link] Image 18 July, 2025 Hanson Wade Bookmark this Oncology Taking chemotherapy directly to skin lesions, with Dr Raza B. Oncology Life Sciences Industry Report - Oncology Developments in the oncology space in 2024 brought hope to both industry and patients.
Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. The deal, disclosed as the biopharma field marked the first day of the annual J.P.
Medicare actuaries expect the drug, which is called Leqembi and sold by Eisai in partnership with Biogen, to cost the traditional Medicare program around $550 million in 2024. That is projected to increase to $3.5 billion in 2025 for the entire Medicare program, a spokesperson for the Centers for Medicare and Medicaid Services confirmed.
The European Medicine Agency’s human medicines committee (CHMP) recommended marketing authorisations for the regulatory approval of three medicines at its January 2024 meeting last week. CHMP’s September 2023 meeting highlights The post CHMP meeting highlights: January 2024 appeared first on European Pharmaceutical Review.
… House Republicans have drafted drug-shortage legislation that differs significantly from the approach Democrats propose to stem shortages of chemotherapies and other critical medicines that hospitals typically use , STAT explains. Republicans We value your postcards and telegrams.
Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.
The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily consists of chemotherapy or Johnson & Johnsons (J&J) Darzalex in combination with chemotherapy.
Immunotherapy in oncology “The addition of pembrolizumab to chemotherapy represents a new frontline therapeutic option for patients with primary advanced or recurrent endometrial carcinoma” Moreover, last week saw US regulatory approval of a combination treatment for endometrial cancer : KEYTRUDA (pembrolizumab) plus chemotherapy.
Here are some of the top regulatory developments from 2024. FDA Approvals in 2024 There were 17 FDA approvals of Biologic License Applications (BLAs), including for Autolus Inc.’s There were also 18 FDA approvals of biosimilar products , including 6 ustekinumab biosimilars and 5 aflibercept biosimilars in 2024 alone.
The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. This initial data on ZL-1310 was presented this week at the EORTC-NCI-AACR (ENA) Symposium 2024.
Updated using the pre|CISION technology, AVA6000 is a kind of generic chemotherapy doxorubicin. By 2024, doxorubicin is anticipated to have a market size of $1.38bn and is extensively utilised as a part of the standard of care in various types of cancers. . It also boosts the drug’s safety, tolerability and efficacy.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content